Undisclosed anti-LAG3 mAb / Protheragen - LARVOL DELTA

Definitely great randomized design to allow early signal finding in the neoadjuvant setting. Good to see anti-LAG3 ab Favezilumab + pembro showing results very consistent w nivo+ relatlimab neoadjuvant data from Prof. Amaria. Biomarker analysis being presented @Liz_htx03 #ESMO2024 poster session soon

An Innovative View: Evaluating Combination Checkpoint Inhibition Strategies in Advanced Melanoma: Considerations with Anti-LAG3 Antibodies (freeCME) - "Released On: March 8, 2023; Expires On: March 8, 2024: Evaluate the pathophysiology of melanoma, including the rationale for use of anti-LAG3 antibodies in combination in advanced melanoma, Assess the latest clinical data and clinical trial opportunities concerning the use of anti-LAG3 antibodies for combination in advanced melanoma, Recognize safety data with combination immunotherapy approaches in advanced melanoma."

Checkpoint inhibition • Online CME